Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19044557 | 1.00 | KDM4E (0.44) | KDM4ECYP1A2TDP1KMT2AMEN1 | |
| SCHEMBL19044559 | 1.00 | KDM4E (0.44) | KDM4ECYP1A2TDP1KMT2AMEN1 | |
| SCHEMBL30018449 | 0.92 | KDM4E (0.43) | KDM4ECYP1A2TDP1KMT2AMEN1 | |
| SCHEMBL16026595 | 0.91 | MEN1 (0.37) | KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL23278004 | 0.84 | HRH3 (0.39) | KDM4EKMT2AMEN1ALDH1A1SIGMAR1 | |
| SCHEMBL1613168 | 0.81 | ATM (0.41) | KDM4EKMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL8695815 | 0.81 | — | — | |
| SCHEMBL19517200 | 0.81 | ATM (0.41) | KDM4EKMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL1303572 | 0.81 | ATM (0.41) | KDM4EKMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL27759935 | 0.81 | KDM4E (0.46) | KDM4ECYP1A2TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178555-A1 | AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPRATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BDR Lifesciences Private Limited (IN) | 2023-05-17 | — | — | EP | claimed |
| CN-115925693-A | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-110461830-B | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-110461830-A | Selective inhibitors of JAK1 | ASTRAZENECA AB | 2019-11-15 | — | — | CN | claimed |
| EP-3353168-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | Dizal (Jiangsu) Pharmaceutical Co., Limited (CN) | 2018-08-01 | — | — | EP | claimed |
| WO-2017050938-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | WO | claimed |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| CN-115925693-B | JAK1 selective inhibitors | 阿斯利康(瑞典)有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118878515-A | Substituted aniline pyrimidine compound and preparation method and application thereof | 河北科技大学 | 2024-11-01 | — | — | CN | disclosed |
| CN-112823159-B | Aromatic heterocyclic compounds with kinase inhibitory activity | 上海轶诺药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4219482-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-0880517-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| CN-1211240-A | Quinazoline derivatives as antitumor agents | ZENECA LTD (GB) | 1999-03-17 | — | — | CN | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| EP-0880517-A1 | QUINAZOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5814630-A | USEFUL AS RECEPTOR TYROSINE KINASE INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-09-29 | — | — | US | disclosed |
| WO-1997030044-A1 | QUINAZOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | KDM4E 77/4885CYP1A2 2808/4885TDP1 4364/4885 |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | JAK1, JAK2, JAK3 | KDM4E 452/4885CYP1A2 976/4885TDP1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.